Industry news

Beijing eyes urban 'super hospitals' in healthcare reform battle

EJ Lane / FeircePharmaAsia

China healthcare policymakers are fighting a losing battle to curb the growth of public urban "superhospitals" that now see expansion as more important than ever in the face of a move in May to scrap a 15% markup on drug prescriptions, Reuters reports.

Medicine Spending Relatively Stable Following Increased Regulatory Data Protection in Canada and Japan

Mark Grayson / PhRMA

There has been much discussion about the effects of adding 12 years of data protection for biologics in the TPP.  However, fears that this could add to the cost of healthcare seem to be unfounded.

Top 10 pharma companies in social media

Beth Snyder Bulik / FiercePharmaMarketing

Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands.

Early antiretroviral therapy prevents non-AIDS outcomes in HIV-infected people

U.S. National Institute of Health

Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals. 

Public markets still open to European biotech; IPO total tops $1.5B, so far

Cormac Sheridan / BioWorld

Cell therapy firm Reneuron plc’s forthcoming £68.4 million (US$106 million) capital increase is further evidence of the continued buoyancy of the public funding environment for European biotech companies.

Price controls fail to improve poor people's access to medicines in India, IMS report says

EJ Lane / FeircePharmaAsia

India's National Pharmaceutical Pricing Authority (NPPA) is busy on both the pharma and device fronts to bring down costs to consumers. But the efforts may do more harm than good, according to an industry-sponsored study by IMS Health Information and Consulting Services India.

Russian-Indian partnership to focus on diagnostics of hereditary diseases

Marchmont Innovation News

The ReadSense genome center based in Troitsk just outside Moscow and India’s Strand Life Sciences, a global leader in bioinformatics for personalized medicine, are pooling efforts in the development of tests for hereditary disease diagnostics,  reported Rusnano, Russia’s largest nanotech company.

From the pharma C-suite: J&J on Asia, emerging markets in Q2

EJ Lane / FeircePharmaAsia

FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan.

Blazing biotech IPO market continues to deliver a fortune for startups

John Carroll / FierceBiotech

The go-go market for biotech IPOs is steaming ahead, pushing two more developers onto Nasdaq with a combined $239 million payoff at above-range prices. And biotech billionaire Patrick Soon-Shiong set a price range on his upcoming IPO for NantKwest at $20 to $23 a share, looking to raise around $160 million--or more--based on a company valuation of $2.2 billion.

Tufts: The vaccine pipeline is soaring and global sales could hit $40B by 2020

Marie Powers / BioWorld

The vaccine product pipeline has never been fuller, with more than triple the number of candidates in development today than in 2005 and global sales on track to reach $40 billion in five years, according to the July/August Impact Report from the Tufts Center for the Study of Drug Development (CSDD).